Ceruvia Lifesciences Receives FDA Investigational New Drug Approval for Psilocybin Obsessive-Compulsive Disorder Program Phase 2 Trial
/PRNewswire/ -- Ceruvia Lifesciences, a leading neurotransformational medicine biopharmaceutical company today announced that the U.S. Food and Drug...
United States Ceruvia Lifesciences Benjamin Kelmedi Christopher Pittenger Carey Turnbull Prnewswire Ceruvia Lifesciences
Source: prnewswire.com